Darzalex loe?

Darzalex (daratumumab)
Darzalex is a human IgG1κ monoclonal antibody that targets CD38, a protein found on the surface of many plasma cells—including the malignant cells that cause multiple myeloma. By binding to CD38, daratumumab flags these cells for destruction by the immune system and can also directly inhibit their growth.

What it’s used for

• Multiple Myeloma:
  • Relapsed/refractory disease after at least one prior therapy.
  • New‑ly diagnosed disease in patients who cannot tolerate or refuse a stem‑cell transplant.
• Monotherapy or in combination with agents such as:
  • Velcade® (bortezomib),
  • Revlimid® (lenalidomide),
  • Velcade + Revlimid combo, or
  • Cyclophosphamide + Revlimid.

How it’s given

• Infusion schedule

  1. Cycle 1–2: 16 mg/kg IV (on days 1, 8, 15, 22).
  2. Cycles 3–6: 4 mg/kg IV (days 1, 8, 15, 22).
  3. Cycle 7 onward: 4 mg/kg IV weekly.

• Infusion time: usually ~90 min for the first infusion, 45 min thereafter (but can be adjusted for patient tolerance).

Common side effects

If you develop a severe infusion reaction (e.g., difficulty breathing, chest pain), stop the infusion and seek immediate medical care.

Contraindications & cautions

• Known hypersensitivity to daratumumab or any of its excipients.
• Active infections: especially uncontrolled viral hepatitis or tuberculosis.
• Immunocompromised patients: increased infection risk.
• Pregnancy/Breastfeeding: insufficient data; generally avoided.

Drug interactions

• Daratumumab is not metabolized by CYP enzymes, so most drug‑drug interactions are unlikely.
• Concurrent immunosuppressants (e.g., steroids, methotrexate) can compound infection risk.
• Antihypertensives: some patients experience transient hypertension during infusion.

Practical tips for patients

1. Pre‑medication: A short course of steroids (e.g., prednisone 40 mg PO) and antihistamines (diphenhydramine 25 mg PO) is often given before the first infusion to reduce reaction risk.
2. Monitoring: Blood counts and liver/kidney panels are checked regularly.
3. Hydration: Adequate fluids before and after the infusion help maintain kidney function.
4. Report symptoms: Any fever, cough, or unusual fatigue should be reported promptly.

Bottom line

Darzalex is a powerful, antibody‑based therapy that has changed the treatment landscape for multiple myeloma, especially for patients who have already tried other regimens. It works by harnessing the immune system to target malignant plasma cells. While it is generally well tolerated, it can cause infusion reactions and increase infection risk, so careful monitoring and pre‑medication are key.

Always discuss any new therapy with your oncology team to weigh benefits versus risks based on your personal health history.